Arimany-Nardi C, Koepsell H, Pastor-Anglada M
Molecular Physiology and Experimental Therapeutics, Department of Biochemistry and Molecular Biology, Institute of Biomedicine (IBUB), University of Barcelona and Oncology Program, National Biomedical Research Institute on Liver and Gastrointestinal Diseases (CIBER EHD), Instituto de Salud Carlos III, Barcelona, Spain.
Department of Molecular Plant Physiology and Biophysics, Julius-von-Sachs-Institute, University Würzburg, Würzburg, Germany.
Pharmacogenomics J. 2015 Dec;15(6):473-87. doi: 10.1038/tpj.2015.78. Epub 2015 Nov 3.
The SCL22A1 gene encodes the broad selectivity transporter hOCT1. hOCT1 is expressed in most epithelial barriers thereby contributing to drug pharmacokinetics. It is also expressed in different drug target cells, including immune system cells and others. Thus, this membrane protein might also contribute to drug pharmacodynamics. Up to 1000 hOCT1 polymorphisms have been identified so far, although only a small fraction of those have been mechanistically studied. A paradigm in the field of drug transporter pharmacogenetics is the impact of hOCT1 gene variability on metformin clinical parameters, affecting area under the concentration-time curve, Cmax and responsiveness. However, hOCT1 also mediates the translocation of a variety of drugs used as anticancer, antiviral, anti-inflammatory, antiemetic agents as well as drugs used in the treatment of neurological diseases among. This review focuses exclusively on those drugs for which some pharmacogenetic data are available, and aims at highlighting the need for further clinical research in this area.
SCL22A1基因编码广泛选择性转运体hOCT1。hOCT1在大多数上皮屏障中表达,从而影响药物的药代动力学。它也在不同的药物靶细胞中表达,包括免疫系统细胞等。因此,这种膜蛋白可能也对药物药效学有影响。到目前为止,已鉴定出多达1000种hOCT1多态性,尽管其中只有一小部分进行了机制研究。药物转运体药物遗传学领域的一个范例是hOCT1基因变异对二甲双胍临床参数的影响,包括浓度-时间曲线下面积、Cmax和反应性。然而,hOCT1也介导多种用作抗癌、抗病毒、抗炎、止吐剂的药物以及用于治疗神经疾病的药物的转运。本综述专门关注那些有一些药物遗传学数据的药物,旨在强调该领域进一步临床研究的必要性。